Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 225 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombotic Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 6:36 PM EDT
Completed No phase listed Observational

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01770951
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome (aHUS)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Dunwoody, Georgia • Chicago, Illinois • Portland, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 23, 2026, 6:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00441090
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions
Placebo, Avatrombopag tablets
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Anaheim, California • Bakersfield, California • Concord, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 1Phase 2 Interventional

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

NCT02401061
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
PRTX-100
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Farmington Hills, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Purple Grape Juice Study

NCT00551746
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Purple Grape Juice
Dietary Supplement
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 23, 2026, 6:36 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

NCT00251277
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise and Inflammation in the Elderly

NCT00753363
View directory record Official record
Conditions
Inflammation, Insulin Sensitivity
Interventions
Weight Loss, Aerobic Exercise Training
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 23, 2026, 6:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Crovalimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
28 Days to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Recruiting Phase 2 Interventional

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT07104565
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
INCA000585
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Not applicable Interventional

Treatment Trial for Post-Thrombotic Syndrome

NCT00633971
View directory record Official record
Conditions
Post Thrombotic Syndrome
Interventions
complex lymphedema therapy
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Jul 23, 2026, 6:36 PM EDT
Completed No phase listed Observational

Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]

NCT03519672
View directory record Official record
Conditions
Congenital Thrombotic Thrombocytopenic Purpura
Interventions
No intervention
Other
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 23, 2026, 6:36 PM EDT
Not listed No phase listed Observational

Venous Thrombectomy/Thrombolysis Outcome Registry

NCT02113475
View directory record Official record
Conditions
Deep Venous Thrombosis, Post Thrombotic Syndrome
Interventions
Not listed
Lead sponsor
Heart and Vascular Outcomes Research Institute
Other
Eligibility
16 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Beverly, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

NCT04056195
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
SKI-O-703, Placebo oral tablet
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 23, 2026, 6:36 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

NCT07421167
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions
ianalumab, thrombopoietin receptor agonist (TPO-RA)
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Stamford, Connecticut • Jacksonville, Florida • Margate, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Not yet recruiting No phase listed Observational

Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors

NCT06358703
View directory record Official record
Conditions
Immune Thrombotic Thrombocytopenia
Interventions
Caplacizumab
Drug
Lead sponsor
US Thrombotic Microangiopathy Alliance
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Groveport, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 3 Interventional Results available

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

NCT00991939
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Dexamethasone USP Micronized, Prednisone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 3 Interventional

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

NCT04543591
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Placebo, Best supportive care
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 100 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Tampa, Florida • Grosse Pointe Farms, Michigan • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 3 Interventional Results available

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT02949128
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome (aHUS)
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Fort Wayne, Indiana • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 1 Interventional

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

NCT00244257
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
GMA161
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jul 23, 2026, 6:36 PM EDT
Terminated Phase 2 Interventional

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544
View directory record Official record
Conditions
Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
Interventions
ARC 1779 Placebo, ARC1779 Injection
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 3 Interventional Results available

The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome

NCT00143598
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Knee-length, graduated elastic compression stocking, Knee-length, placebo stocking
Device
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 23, 2026, 6:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

NCT02281370
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Eltrombopag, Cyclosporine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 23, 2026, 6:36 PM EDT